Catalyst Pharmaceuticals, Inc.

NASDAQ•CPRX

CEO: Mr. Richard John Daly M.B.A.

Sector: Healthcare

Industry: Biotechnology

Listing Date: 2006-11-08

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

Contact Information

355 Alhambra Circle, Suite 801, Coral Gables, FL, 33134, United States

305-420-3200

www.catalystpharma.com

Market Cap

$2.87B

P/E (TTM)

13.3

17.2

Dividend Yield

52W High

$26.58

52W Low

$19.05

52W Range

57%

Rank32Top 23.6%

4.9

F-Score

Modified Piotroski Analysis

Based on 10-year fundamentals

Average • 4.9 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2016-2025

Financial Dashboard

Q4 2025 Data

Revenue

$152.61M+0.00%

4-Quarter Trend

EPS

$0.42+0.00%

4-Quarter Trend

FCF

$44.86M+0.00%

4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Total Revenue Rises 20.0% Total revenues reached $589.0M USD in 2025, marking a 19.8% increase driven by strong product sales growth.

Net Income Jumps 30.8% Net income was $214.3M USD in 2025, reflecting substantial profitability improvement over the prior year period.

AGAMREE Sales Accelerate AGAMREE® net product revenue grew significantly to $117.1M USD in 2025 following its March 2024 commercial launch.

Risk Factors

FIRDAPSE Litigation Uncertainty Pending Paragraph IV trial against Hetero scheduled for March 2026; outcome impacts generic entry timing before 2035.

FYCOMPA Revenue Declining FYCOMPA® net product revenue fell 17.4% to $113.3M USD due to generic competition following patent exclusivity loss.

Reliance on Third-Party Supply Business success depends on contract manufacturers; failure to maintain cGMP compliance risks supply interruptions and delays.

Outlook

Portfolio Expansion Strategy Strategy focuses on acquiring immediate, near-term accretive assets targeting rare (orphan) disease therapeutic categories.

AGAMREE Manufacturing Transition Currently transitioning AGAMREE® final goods manufacturing to a U.S. location, estimated completion expected by the end of 2026.

Share Repurchase Program Active Board authorized up to $200M USD share repurchase program spanning October 2025 through December 2026.

Peer Comparison

Revenue (TTM)

APLS

$1.00B

+28.5%

KNSA

$677.56M

+60.1%

FOLD

$634.21M

+20.0%

Gross Margin (Latest Quarter)

AGIO

96.9%

-4.3pp

BEAM

95.0%

-471.3pp

ARQT

91.0%

+3.5pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
IBRX	$8.44B	-23.1	64.3%	175.0%
CDTX	$5.61B	-18.6	-60.1%	0.4%
FOLD	$4.51B	-163.8	-12.0%	50.9%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

2.6%

Moderate Growth

4Q Net Income CAGR

-2.4%

Stable Profitability

Cash Flow Stability

100%

Strong Cash Flow

Deep Research

Next earnings:May 5, 2026

EPS:-

Revenue:-

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data